Incidence and predictors of loss to follow-up among adult HIV-infected patients taking antiretroviral therapy at North Shewa zone public Hospitals, Northeast Ethiopia: A retrospective follow-up study

Wondimeneh Shibabaw Shiferaw¹, Abebe Muche Belete², Alemu Adela², Mekasha Getnet¹, Yared Asmare Aynalem¹

1. Department of Nursing, College of Health Science, Debre Berhan University, Ethiopia.
2. Department pre-clinical, College of Medicine, Debre Berhan University, Ethiopia.

Abstract

Background: Patients who are lost to follow-up while on treatment compromise their own health and the long-term success of antiretroviral therapy (ART) programs. Besides, loss to follow-up (LTFU) increases HIV-related morbidity and mortality. Therefore, this study aimed to determine the incidence of LTFU and its predictors among adult HIV positive patients on anti-retroviral therapy at North Shoa zone public hospitals, Northeast Ethiopia.

Methods: A retrospective follow up study of 517 people living with HIV/AIDS and attending an ART clinic between 2015 and 2020 was conducted at North Shewa zone, public hospitals. Kaplan-Meier failure function together with log rank test was used to compare failure function. Multivariable Cox proportion hazards regression model was used to determine predictors of LTFU.

Result: The incidence density rate of lost to follow up among HIV positive adult on ART was found to be 8.9 per 100 adult years observation (95%CI; 7.45, 10.68). In multivariable cox proportional regression analysis, WHO clinical stage-IV (AHR = 1.50; 95% CI: 1.08, 3.75), comorbidity disease (AHR = 0.54; 95% CI; 0.30, 0.97), body mass index less than 18kg/m² (AHR = 1.60; 95% CI; 1.02, 2.51), cotrimoxazole preventive therapy (AHR = 1.57; 95% CI;1.09, 2.53), and a low CD4 count (AHR = 1.66; 95% CI; 1.29, 3.49) were found to be a significant predictors of lost to follow up.

Conclusion: The current study showed that the incidence rate of loss to ART follow-up was high. Body mass index score less than 18kg/m², advanced WHO clinical stage, CD4<200cell/mm³, had comorbidity disease, and cotrimoxazole therapy were a significant predictors of lost to ART follow up. Therefore, appropriate mitigation measures in the at-risk group need to be instigated to advance retention rate.

Keywords: ART, HIV/AIDS, lost to follow up, predictors, Ethiopia.

DOI: https://dx.doi.org/10.4314/abs.v22i2.3

Cite as: Shiferaw WS, Belete AM, Adela A, Getnet M, Aynalem YA. Incidence and predictors of loss to follow-up among adult HIV-infected patients taking antiretroviral therapy at North Shewa zone public Hospitals, Northeast Ethiopia: A retrospective follow-up study. Afri Health Sci. 2022;22(2): 12-26. https://dx.doi.org/10.4314/abs.v22i2.3

Background

Human Immunodeficiency Virus (HIV) has been a global challenge for the past three decades. In 2017, nearly 36.9 million People living with HIV (PLHIV) worldwide, of these 35.1 million were adults, and about 19.6 million are in Eastern and southern Africa making up 53.1% of PLHIV in the region¹. Sub-Saharan Africa (SSA) carries the highest burden with an estimated 24.7 million PLHIV, nearly 71% of the global total². There has been an increasing in number of PLHIV in Ethiopia, estimated number of PLHIV were 710,000 people are still infected, with adult greater than 15 years, and the estimated adult prevalence making up 1.1%³,⁴.

Evidence showed that ART significantly reduced mortality and improved life expectancy of HIV-infected patients, but the attainment depends on regular patient follow-up⁵. The goals of ART are maximal and durable suppression of viral replication to prevent development of HIV drug resistance and treatment failure, restoration and/or preservation of immunologic function, reduction of HIV-related morbidity and mortality, improving the quality of life⁶. As ART coverage expands, a rise in loss to follow-up (LTFU) has been observed in many ART programs in Sub-Saharan Africa⁷.

The high levels of adherence to ART and retention in HIV care programs is critical to achieve optimal health.
outcomes among PLHIV. However, LTFU has a significant clinical and epidemiological challenge, which compromises long term patients’ survival. Besides, it negatively impacts on the immunological benefit of ART and increases AIDS-related morbidity, mortality, and hospitalizations. Moreover, it would result in serious consequences, such as drug toxicity, treatment failure, and drug resistance.

Several studies showed that the predictors of lost to follow up were daily laborer, ambulatory functional status, not take opportunistic prophylaxis, being underweight, jobless, substance abuser, having sub-optimal adherence, having opportunistic infections, having CD4 count <200 cells/µL, old age, female gender, and advanced disease stage. The incidence of LTFU was estimated to be 103 per 1000 person-years in South Africa, 10 per 100 in Zambia, 52.9 per 100 person-years in Kenya, 11.6 per 100 person-years in northwest Ethiopia. Although previous studies have explored risk factors associated with LTFU from ART programs, the problem is highest remains a key challenge for program planners. Therefore, it needs further exploration of predictors of LTFU. Besides, there was limited evidence on the incidence of LTFU and its predictors in the study area. Hence, this study aimed to estimate the incidence of LTFU and its predictors among HIV positive adult patients on ART at North Shewa zone public hospitals, Northeast Ethiopia. Findings will be important evidence to know burden of the problem to develop management and preventive measures.

Methods

Study setting

The study was conducted in North Shewa Zone, public hospitals, Northeast Ethiopia. North Shewa Zone is one of the 13 Zones in Amhara administrative regional state and the City is Debre Berhan Town located, 695 km from Bahir Dar, capital of the region and 130 km from Addis Ababa, capital of Ethiopia. It is border on the south and the west by the Oromia region, on the North by South Wollo, on the North East by the Oromia zone, and the East by the Afar region. It covers an area of 15,936.13 square kilometers. It has 27 districts with different climate (dega, woyneadega & kola). The major ethnic groups of the zone are Amhara. The population is predominantly Orthodox-Christian by religion followed by Muslim. Agriculture is the main livelihood of the population. The Zone has 11 hospitals (10 of which are public). Out of the 10 public hospitals, two are general hospitals; one is comprehensive specialized hospital and the rest 7 are primary hospitals. According to North Shoa zonal health office report of 2017 for comprehensive ART services (HIV/AIDS care) in all health facilities, on these selected hospitals the total of 3406 HIV-positive adult patients were received clinical care. The study was conducted among the selected four public hospitals (Debre Berhan Comprehensive Specialized Hospital, Enat Primary Hospital, Mehal Meda Primary Hospital, and Ataye Primary Hospital).

Study design and population

A five-year institution based, retrospective follow up study was conducted at North Shewa zone public hospitals from February 1 to March 15, 2020. All adult HIV/AIDS patients who were newly initiated ART and enrolled at selected north shoa zone public hospitals, ART clinic during the required time (i.e. January 2015 to January 2020) was considered in the current study. Besides, clients who had diagnosis and initiated ART at other health institution and subsequently referred to the respective selected hospital for further treatment was included. On the other hands, HIV positive adult patients, whose medical charts were not found and having incomplete data were excluded from the study.

Sample size, sampling technique, and covariates

The sample size was determined using double population proportion formula by considering WHO clinical stage as the major predictor variables using Epi info version 7 statistical package. Based on the available evidence the final sample size determined for this study was 517 HIV/AIDS patients’ charts. The estimated sample size was proportionally allocated to each selected four hospitals according to their total population and the data were collected by systematic random sampling. The sampling intervals of the hospitals are different which was determined by dividing the total number of ART patients chart in the specific hospital to the allocated sample size (N/n) th. The first patient medical chart was selected randomly from the registration book and every K patient chart for all selected hospital was selected. The incidence of lost to follow up among HIV positive adult patients on ART was the outcome variable. On the other hand, age, gender, residence, body mass index, opportunistic infection, functional status, HAART regimen, WHO clinical stage, CD4 count, contact person, disclosure status, and cotrimoxazole preventive therapy were the independent variables.
Data collection tool
A data abstraction format was developed from the standardized ART entry and follow-up form currently used by the ART clinics. The data were extracted by reviewing patients' ART medical charts. Lost to follow up was confirmed by reviewing medical registration in each hospital. The data abstraction format was examined by senior experts in the area of study for content validity. Data abstraction was designed based on study objectives. This included socio-demographic characteristics, baseline clinical information, and treatment outcomes were obtained from patients’ medical charts. These clinical and treatment-related predictors were taken into consideration at the starting of ART was used as a baseline value. Data were retrieved from patients' ART charts by trained nurses working in the ART clinic using uniform data abstraction format prepared for the study.

Data Collection Procedure
All available information on patient records were checked then the appropriate data extraction format was adopted in English in order to extract all the relevant variables to meet the study objectives. The starting point for retrospective follow-up was the time from the first initiation of ART among HIV positive adult patients and the endpoint was the date of lost to follow up, death, transfer, or date of last contact until January 1st, 2020. The chart of HIV positive adult patients enrolled on ART from January 1, 2015 to January 1st, 2020 at selected four hospitals was retrieved from ART registries. The record of all study participants was selected according to pre-specified eligibility criteria. Time to lost to follow up was calculated as the time between the date of ART initiation and the date of lost to follow up. In the current study, HIV positive patients were considered as censored, if transfer to other health care institution (based on report) date or last visit date) or if they were alive at the end of the study period (January 1st, 2020). Before collecting the data, baseline and follow-up records were reviewed and the registration was identified by their medical record number. The data collectors who are working at the ART clinic were extracted and reviewed the charts.

Data Quality Control
To ensure the quality of the data pretest was conducted with 5% of the data abstraction format. Any error found during the process of checking was corrected and modification was made into the final version of the data abstraction format. Training on record review was given to data collectors and supervisors for 01 days before actual data collection task. Besides, the data quality was controlled by designing the proper data collection materials, and through continuous supervision. The collected data form was examined for completeness and consistency during data entry, storage, cleaning, and analysis. The principal investigator of the study was control the overall activity.

Data Analysis
Data were coded, cleaned, and entered using EPI-data 3.1 and exported to STATA 14 statistical software for analysis. Kaplan-Meier failure function together with log rank test was used to test for the presence of difference in lost to follow up among categories of covariates. Appropriate descriptive statistics were used based on the nature of the data. Bivariable Cox regression analysis was first fitted and those independent variables, with a p-value ≤ 0.25 level of significance, were included in the multivariable analysis. Multivariable Cox proportional-hazard regression was fitted at 5% level of significance to determine the net effect of each independent variable on lost to follow up after initiation of ART among HIV positive adult patients. To verify the proportionality assumption in Cox's model, we tested the correlation between survival time and Schoenfeld's standardized residuals. The result of this study was expressed as hazard ratios (HRs) with 95% confidence interval. Finally, the result of the study was presented with text, graph, and table.

Result
Socio-demographic characteristics of the study participants
The median age of the respondents was 34 (IQR: 28-40 years) and nearly half (41%) of them were under the age category of 25-34 years. With respect to sex of the participants about 265(52.27%) were male. Majority, 347(68.44%) of the participants were urban by residence. Nearly half, 240(47.34%) of the participants were married. Majority, 392(77.32%) of the respondents are orthodox religion followers. One hundred seventy two (33.93%) of the respondents have no formal education and only 20.2% have higher educational level. Regarding occupational status nearly one third, 144(28.4%) has self-employee work. Most of them, 410 (80.87%) have contact person during their follow up care (Table 1).
Table 1. Socio-demographic characteristics HIV/AIDS patients on ART

| Variable          | Category    | Frequency | Percent (%) |
|-------------------|-------------|-----------|-------------|
| **Sex**           | Male        | 265       | 52.27       |
|                   | Female      | 242       | 47.73       |
| **Age**           | 15-24       | 59        | 11.64       |
|                   | 25-34       | 208       | 41.03       |
|                   | 35-44       | 151       | 29.78       |
|                   | >45         | 89        | 17.55       |
| **Residence**     | Rural       | 160       | 31.56       |
|                   | Urban       | 347       | 68.44       |
| **Marital status**| Married     | 240       | 47.34       |
|                   | Single      | 102       | 20.12       |
|                   | Divorced    | 125       | 24.65       |
|                   | Widowed     | 40        | 7.89        |
| **Religion**      | Orthodox    | 392       | 77.32       |
|                   | Muslim      | 87        | 17.16       |
|                   | Other*      | 28        | 5.52        |
| **Occupation**    | Daily labor | 64        | 12.62       |
|                   | Farmer      | 88        | 17.36       |
|                   | Government employee | 107 | 21.10 |
|                   | Self-employee | 144 | 28.40 |
|                   | Student     | 27        | 5.33        |
|                   | House wife  | 77        | 15.19       |
| **Educational status** | No formal education | 172 | 33.93 |
|                   | Primary school | 136 | 26.82 |
|                   | Secondary school | 97 | 19.13 |
|                   | Higher education | 102 | 20.12 |
| **Contact person**| Yes         | 410       | 80.87       |
|                   | No          | 97        | 19.13       |

**NB**: other*; catholic and protestant

Clinical related characteristics
Nearly one third, 158 (31.16%), had opportunistic infections, of these 86 (54.43%) had Tuberculosis, 32 (20.25%) bacterial pneumonia, and 16 (10.13%) other opportunistic infections. Nearly one quarter, 122 (24.06%) had comorbidity disease at baseline. Regarding body mass index more than one quarter, 138 (27.22%) had less than 18.5 kg/m². The majority of the participants, 379 (74.75%), were at working functional status. Regarding the WHO clinical stage over one third 194 (38.26%) were clinical stage I, while one third, 166 (32.74%) were clinical stage III. Majority, 411 (81.07%) of the study participants were disclosed their status to anyone (Table 2).
| Variables                        | Category     | Frequency | Percent (%) |
|---------------------------------|--------------|-----------|-------------|
| Opportunistic infection         | Yes          | 158       | 31.16       |
|                                 | No           | 349       | 68.84       |
| Type of Opportunistic infection | Herpes zoster | 7         | 4.43        |
|                                 | Pneumonia    | 32        | 20.25       |
|                                 | Tuberculosis | 86        | 54.43       |
|                                 | Oral thrush  | 17        | 10.76       |
|                                 | Other*       | 16        | 10.13       |
| Comorbidity                     | Yes          | 122       | 24.06       |
|                                 | No           | 385       | 75.94       |
| Body mass index                 | < 18.5       | 138       | 27.22       |
|                                 | 18.5-24.9    | 328       | 64.69       |
|                                 | ≥ 25.0       | 41        | 8.09        |
| functional status               | Working      | 379       | 74.75       |
|                                 | Ambulatory   | 115       | 22.68       |
|                                 | Bedridden    | 13        | 2.56        |
| Hemoglobin (mg/dl)              | Normal       | 411       | 81.07       |
|                                 | Anemic       | 96        | 18.93       |
| WHO clinical staging            | Stage I      | 194       | 38.26       |
|                                 | Stage II     | 127       | 25.05       |
|                                 | Stage III    | 166       | 32.74       |
|                                 | Stage IV     | 20        | 3.94        |
| Baseline CD4                    | <200         | 125       | 24.65       |
|                                 | 200-500      | 337       | 66.47       |
|                                 | >500         | 45        | 8.88        |
| Disclosure status               | Disclosed to any one | 411 | 81.07 |
|                                 | Not disclosed to any one | 96 | 18.93 |

NB: Other*;

**Treatment related characteristics**

Nearly one third, 156 (30.77%) of the patients were eligible for ART by WHO clinical stage and total lymphocyte count, while 151 (29.78%) were so by CD4 cell count criteria. Cotrimoxazole Preventive Therapy (CPT) was given to 338 (66.67%) study participants. More than half, 278 (54.83%), of the patients started ART treatment with TDF–3TC–EFV and 36 (6%) changed to another regimen within the first line, and while 111 (21.89) were used AZT-3TC-NVP regimens. One fourth, 132 (26.04%) of study participants had reported drug side effect (Table 3).
Table 3. Treatment related characteristics of participants among HIV/AIDS patients on ART.

| Variable                      | Category                        | Frequency | Percent |
|-------------------------------|---------------------------------|-----------|---------|
| ART eligibility criteria      | CD4<350, 500                    | 151       | 29.78   |
|                               | WHO stage IV                    | 14        | 2.76    |
|                               | WHO stage II and III with TLC<120| 156       | 30.77   |
|                               | No criteria                      | 186       | 36.69   |
| HAART regimens given          | 1c(AZT-3TC-NVP)                 | 111       | 21.89   |
|                               | 1d(AZT-3TC-EFV)                 | 45        | 8.87    |
|                               | 1e(TDF-3TC-EFV)                 | 278       | 54.83   |
|                               | 1f(TDF-3TC-NVP)                 | 36        | 7.10    |
|                               | Others*                         | 37        | 7.29    |
| Cotrimoxazole prophylaxis     | Given                           | 338       | 66.67   |
|                               | Not given                       | 169       | 33.33   |
| Drug side effect              | Yes                             | 132       | 26.04   |
|                               | No                              | 375       | 73.96   |
| Last follow up status         | Lost to follow up               | 118       | 23.27   |
|                               | Alive                           | 363       | 71.59   |
|                               | Death                           | 18        | 3.55    |
|                               | Transfer                         | 8         | 1.58    |

**NB:** others*; 1J (TDF+3TC+DTG), and 2h (TDF+3TC+ATV/r)

**Incidence of lost to follow up**

There were 118 cases of LTFU observed over 1,322 person years at risk. The incidence rate of lost to follow up was 8.9 per 100 person years observation (95%CI; 7.45, 10.68). The incidence proportion of lost to follow up in the cohort was 23.27%. The study participants were followed for a median of 32.46 months (IQR: 15.63–45.05) after initiation of ART. The probability of lost follow up among ART patients was 6.32%, 13.16%, 20.74%, 34.24%, and 43.59% at 1, 2, 3, 4, and 5 years of follow up respectively (Fig. 1). The overall lost to follow up failure rate of the cohort during 5 years follow up was 43.59%. The cumulative probability of LTFU among different groups of ART patients by their WHO clinical stage (Fig. 2), baseline anemic status (Fig.3), comorbidity (Fig.4), and cotrimoxazole therapy (Fig.5) were compared graphically.
Figure 1. The overall hazard rate of lost to ART follow-up among HIV-positive adult individuals at North Shoa, public hospitals, Northeast Ethiopia.

Figure 2. The hazard rate of lost to follow-up of HIV-positive adults on ART by their WHO clinical stage.
Figure 3. The hazard rate of lost to follow-up of HIV-positive adults on ART by their baseline anemic status.

Figure 4. The hazard rate of lost to follow-up of HIV-positive adults on ART by their comorbidity status.
Testing overall model fit

This figure shows if the cox regression model fits the data, these residuals should have a standard censored exponential distribution with hazard ratio. If we comparing the jagged line with the reference line, we observe that, the cox model does fit these data to reasonable. The hazard function follows the $45^\circ$ line very closely. Hence, the output shows cox-snell residuals were satisfied the overall model fitness test (Fig. 6).

Figure 5. The hazard rate of lost to follow-up of HIV-positive adults on ART by their cotrimoxazole therapy

Figure 6. Cox-Snell residual Nelson–Aalen cumulative hazard graph on lost to follow up in North Shoa zone, public hospitals, northeast Ethiopia
Predictors of lost to follow up among adult ART clients using the Cox proportional regression model

Adults HIV/AIDS patients on ART who were on WHO clinical stage-IV increased the hazard ratio of LTFU by 1.5 (AHR = 1.50; 95% CI: 1.08, 3.75) times as compared to adults in clinical stages I. Having comorbidity disease at baseline were lowered the hazard ratio for LTFU by 46% (AHR = 0.54; 95% CI 0.30, 0.97) as compared to their counter parts. Body mass index less than 18k/m2 were increased the hazard ratio for LTFU by 60% (AHR = 1.60; 95% CI 1.29, 3.49) as compared with normal weight patients. Those who taken cotrimoxazole preventive therapy were increased the hazard ratio for LTFU by 57% (AHR = 1.57; 95% CI 1.09, 2.53) as compared with don’t taken cotrimoxazole therapy. Adults patients who started ART with a baseline CD4 cell count of under 200 cell/m3 were 66% more likely to be LTFU compared to those with a baseline CD4 cell count of greater than 500 cell/m3 (AHR = 1.66, 95% CI, 1.29, 3.49), (Table 4).

Table 4. Predictors of lost to follow up among adult ART clients at North Shewa, public hospitals, northeast Ethiopia.

| Variables                      | Category | Lost to follow up | CHR with 95%CI | AHR with 95%CI |
|--------------------------------|----------|-------------------|----------------|----------------|
| Age in years                   | 15-24    | Yes | 17 | 42 | 1 |
|                                | 25-34    | No  | 160 | 74 | 0.74 (0.42, 1.30) | 0.72 (0.49, 1.29) |
|                                | 35-44    | No  | 117 | 69 | 0.69 (0.37, 1.24) | 0.61 (0.32, 1.16) |
|                                | >45      | No  | 70 | 72 | 0.72 (0.37, 1.40) | 0.66 (0.33, 1.33) |
| Contact person                 | Yes      | Yes | 93 | 25 | 1.34 (0.86, 2.09) | 1.39 (0.82, 2.36) |
|                                | No       | No  | 72 | 25 | 1.18 (0.80, 1.72) | 1.20 (0.80, 1.72) |
| Opportunistic infection        | Yes      | Yes | 40 | 40 | 1.08 (0.73, 1.58) | 1.50 (0.91, 2.46) |
|                                | No       | No  | 118 | 40 | 1.50 (1.09, 2.10) | 1.50 (1.09, 2.10) |
| Comorbidity                    | Yes      | Yes | 95 | 23 | 0.76 (0.48, 1.20) | 0.54 (0.30, 0.97)* |
|                                | No       | No  | 290 | 95 | 1.00 (0.63, 1.58) | 1.00 (0.63, 1.58) |
| Baseline Body mass index       | <18.5    | Yes | 37 | 37 | 1.16 (0.74, 1.83) | 1.19 (0.69, 2.06) |
|                                | 18.5-24.9| Yes | 101 | 76 | 1.31 (1.08, 2.14) | 1.60 (1.02, 2.51)* |
|                                | >25.0    | Yes | 252 | 76 | 1.60 (1.02, 2.51)* | 1.60 (1.02, 2.51)* |
| Disclosure status              | Disclosed to any one | Yes | 95 | 23 | 0.72 (0.37, 1.40) | 0.66 (0.33, 1.33) |
|                                | Not disclosed to any one | No  | 316 | 73 | 1.00 (0.63, 1.58) | 1.00 (0.63, 1.58) |
| Baseline CD4                   | <200     | Yes | 37 | 37 | 1.47 (1.06, 2.27)* | 1.66 (1.29, 3.49)* |
|                                | 200-500  | Yes | 71 | 71 | 0.83 (0.42, 1.61) | 0.55 (0.26, 1.18) |
|                                | >500     | Yes | 10 | 10 | 1.00 (0.63, 1.58) | 1.00 (0.63, 1.58) |
| Baseline Hemoglobin(g/dl) (logbook) | Normal | Yes | 93 | 93 | 1.24 (0.79, 1.92) | 1.01 (0.61, 1.66) |
|                                | Anemia   | Yes | 318 | 25 | 1.24 (0.79, 1.92) | 1.01 (0.61, 1.66) |
| Baseline WHO clinical stage    | Stage I  | Yes | 44 | 44 | 1.24 (0.79, 1.92) | 1.01 (0.61, 1.66) |
|                                | Stage II | Yes | 95 | 32 | 1.12 (0.71, 1.76) | 0.89 (0.53, 1.52) |
|                                | Stage III| Yes | 131 | 35 | 0.95 (0.61, 1.48) | 0.82 (0.47, 1.43) |
|                                | Stage IV | Yes | 13 | 41 | 1.24 (0.79, 1.92) | 1.01 (0.61, 1.66) |
| HAART regimen                  | 1f(TDF-3TC-NVP) | Yes | 7 | 7 | 2.43 (1.09, 5.40)* | 1.50 (1.08, 3.75)* |
|                                | 1c(AZT-3TC-NVP) | Yes | 35 | 35 | 1.44 (0.64, 3.26) | 1.98 (0.82, 4.78) |
|                                | 1d(AZT-3TC-EVF) | Yes | 4 | 4 | 0.40 (0.12, 1.38) | 0.47 (0.13, 1.72) |
|                                | 1e(TDF-3TC-EVF) | Yes | 66 | 212 | 1.26 (0.57, 2.75) | 1.56 (0.68, 3.61) |
| Cotrimoxazole Therapy          | Not given | Yes | 36 | 36 | 1.46 (1.28, 2.16)* | 1.57 (1.09, 2.53)* |
|                                | Given    | Yes | 256 | 82 | 1.46 (1.28, 2.16)* | 1.57 (1.09, 2.53)* |

NB; *p-value <0.05 ; 1= reference group
Discussion
This study mainly assessed the incidence and predictors of LTFU among adult HIV patients on ART in North Shewa zone, public hospitals, northeast Ethiopia. In this study the incidence rate of LTFU was found to be 8.9 per 100 person year. The finding was consistent with studies done in different regions of Ethiopia\(^{14,27}\), and South Africa\(^{28}\). The observed similarity might be due to the standardized implementation of ART services based on the WHO ART guideline. However, the current finding was lower than a study done in Guinea-Bissau\(^{29}\), Uganda\(^{30}\), Colombia\(^{31}\), and different areas of Ethiopia\(^{15,32}\). The possible variation among these studies could be accounted for by the different LTFU definitions for patients on ART have been proposed ranging from 60 days after a missed appointment to 180 days after the date of the last visit\(^{33,34}\). Besides, the observed difference might be due to the study period in which currently, beginning from 2016, test and treat strategy is introduced in Ethiopia and this might increase the number of patients on follow up. Moreover, despite the relatively low rate of LTFU in our study, it is imperative to aim at retaining all patients on treatment since LTFU may leads to negative health outcomes such as the spread of HIV infection and deaths.

On the other hands, the present study was higher than different studies done in Uganda\(^{20}\), Debre Markos-Ethiopia\(^{33}\), Yunnan province\(^{36}\), and Asia\(^{37}\). Lost to follow up in our study was found to be higher than the other studies as explained above it might be due to there have been a variety of study definitions with a vast diversity of LTFU estimates makes comparisons between studies difficult. Likewise, evidence supported that the estimates of LTFU in different areas of sub-Saharan Africa are likely to be overestimated due to the absence of active tracing strategies\(^{38}\). Furthermore, the main reasons in rising incidence of LTFU have been attributed to poor patient tracing in the low-income setting and due to lack of reporting the risk of death events that can be considered as LTFU\(^{39}\). According to the present study having a body mass index (BMI) score of less than 18.5 kg/m\(^2\) were [AHR: 1.60, 95%CI; 1.02, 2.51] found to be at higher risk of LTFU from adult ART treatment programs using 18.5-24.9 kg/m\(^2\) as reference. This finding is consistent with studies conducted in Tanzania\(^{19}\), Kenya\(^{40}\), and Northwest Ethiopia\(^{15}\). The observed similarity might be attributed to patients who were under-weight, may have had comitant opportunistic infections related to malnutrition and some may die from such conditions but were never reported to the HIV clinic due to the passive reporting mechanism. Besides, studies showed that lower BMI have been reported to be associated with HIV mortality and progression to AIDS\(^{41-43}\). Furthermore, this could be due to the fact that underweight patients may have had worse baseline health and less healthy food intake to have the energy to visit frequently the clinics and keep their appointments than patients who are normal weight.

In the current study, the hazard of loss to follow among WHO clinical stage IV was 1.5 times higher as compared to clinical stage I (AHR = 1.50, 95% CI; 1.08, 3.74). A similar finding was reported by a study conducted in Tanzania\(^{19}\), in different areas of Nigeria\(^{44,45}\), and Ethiopia\(^{35,46}\). This could be explain by the fact that patients classified as WHO clinical stage 3 or 4 shows higher probability of infections and are bed ridden most of the time. This is likely to make their continued engagement with the HIV clinic difficult. Besides, the association between LTFU and advanced WHO clinical disease suggest that unrecognized mortality explains a proportion of LTFU among study participants\(^{47}\).

We observed that patients with baseline CD4 cell count less than 200 cells/mm\(^3\) were more likely to be LTFU. This finding was supported by studies conducted in Yunnan province\(^ {36}\), South Africa\(^{48}\), and different areas of Ethiopia\(^{18,46,49}\). The possible explanation might be patients with a low CD4 cell count may be prone to LTFU due to significant HIV-related symptoms. Besides, patients at risk of progression could choose to live close to their family or could be transferred to another clinic and thus be lost to follow-up in the previous center. Moreover, evidence showed that patients with low CD4 cell counts are likely to be in advanced WHO clinical stage of HIV/AIDS, which prone to opportunistic infections and an elevated risk of mortality\(^{50,51}\). In contrary to previous studies\(^{14,25}\), the current finding showed that patients who had been taken cotrimoxazole preventive therapy were increased the hazard ratio of LTFU. The observed difference in these studies may be due to the variation in confounding variables that were not controlled by the respective studies as it could affect the true effect of cotrimoxazole therapy on LTFU.

The current study found that the risk of LTFU among those who had comorbidity disease was reduced by 46%
(AHR 0.54; 95% CI 0.30, 0.97) compared with those had no comorbidity disease. It is in accordance with the study conducted in Nigeria\(^{30}\). This might be due to the fact that the co-existence of comorbidity, patients may seek health care institution frequently. As evidence showed that co-morbidity increases with HIV severity and the greater prevalence of comorbidities among people living with HIV/AIDS (PLWHA) may be attributed to antiretroviral toxicity or caused by the HIV infection itself \(^{52}\). In addition, a study had done in London showed that 29% of HIV patients have at least one comorbid disease\(^{53}\). Moreover, thought HIV-non-communicable disease (NCD) comorbidity causes an additional burden to PLWHA because of increased transport costs, NCD prescribed medication expenses and more productive days lost due to illness compared with HIV alone\(^{54}\). The present study had certain limitations that should be taken into account while interpreting these findings. First, we used secondary chart review; excluding of incomplete data may leads to selection bias. Second, patients, who were considered as LTFU might have been died or self-referred to other facilities. Third, since this study used baseline socio-demographic, clinical and treatment related factors, there may be a change of these variables after a time.

**Conclusion**

In the current study the incidence rate of LTFU among adult HIV/AIDS patients on ART was found to be high. Body mass index score less than 18kg/m\(^2\), advanced WHO clinical stage, CD4<200cell/mm\(^3\), had comorbidity disease, and using of cotrimoxazole therapy were statistical associated to LTFU. Therefore, policymaker and other concerned bodies should implement situation based and context specific preventive measure on these identified factors.

**Abbreviations**

AIDS: Acquired Immunodeficiency syndrome; AHR: Adjusted hazard Ratio; ART: anti-retroviral treatment; CI: Confidence Interval; CHR: Crude Hazard ratio; LTFU: lost to follow up; HIV: Human Immunodeficiency Virus; PLWHA: people living with HIV/AIDS; NCD: Non-communicable disease; WHO: World Health Organization.

**Authors’ contributions**

WSS contributed to generating topics, writing proposals, data collection, analyses, development of the manuscript, processed publication. AMB, AA, MG, and YAA contributed to reviewing the paper, assisted in data collection and analyses, and critically reviewed the manuscript. All authors contributed to data analysis, drafting or revising the article, have agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

**Ethical Approval and consent to participate**

Ethical clearance was obtained from the ethical review committee of College of Health Science Debre Berhan University with institutional research ethics review committee number of (IRB protocol: DBU/CHS/MN/SG11/2020). Permission was obtained from each included hospital medical director office. Since this study used an analysis of secondary data from patient charts, we received a waiver for informed consent. To keep the confidentiality names and other personal identifiers were not included in the data collection tool. This study was conducted in accordance with the Declaration of Helsinki.

**Consent for publication**

Not applicable.

**Funding:**

This research was funded by Debre Berhan University with project Code: GOV/DBU/TH12/CHS/N/03/19. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Availability of data and materials**

The data used to support the findings of this study are included in the article.

**Competing interests**

The authors declare that they have no competing interests.

**Acknowledgments**

First of all, we want to give appreciation to Debre Berhan University, College of Health Science research coordination office for giving us this chance to participate in the
research activity. We would like to thank the data collectors, and supervisors who were involved in this study and spent their valuable time responding to our study.

References
1. HIV/AIDS JUNPo: Global HIV & AIDS statistics—2018 fact sheet. UNAIDS org (http://www.unaids.org/en/resources/fact-sheet)[Accessed August 8, 2018] Export Citation 2018.
2. Kharsany AB, Karim QA: HIV infection and AIDS in sub-Saharan Africa: current status, challenges and opportunities. The open AIDS journal 2016, 10:34.
3. World Health Organization: Progress report 2016: prevent HIV, test and treat all: WHO support for country impact. In.: World Health Organization; 2016.
4. UNAIDS W: Global AIDS monitoring. Geneva: UNAIDS 2017.
5. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Plotto JH: Prevention of HIV-1 infection with early antiretroviral therapy. New England journal of medicine 2011, 365(6):493-505.
6. Kenya A: STI Control Programme. Kenya AIDS indicator survey 2012, 2014.
7. Mberi MN, Kuonza LR, Dube NM, Nattey C, Manda S, Summers R: Determinants of loss to follow-up in patients on antiretroviral treatment, South Africa, 2004–2012: a cohort study. BMC Health Services Research 2015, 15(1):1-11.
8. Movahed E, Morowatisharifabad MA, Farokhzadian J, Nkooie R, Hosseinzadeh M, Askarihahi M, Bidaki R: Antiretroviral therapy adherence among people living with HIV: directed content analysis based on information-motivation-behavioral skills model. International Quarterly of Community Health Education 2019, 40(1):47-56.
9. Estill J, Tweya H, Egger M, Wandeler G, Feldacker C, Johnson LF, Blaser N, Vizcaya LS, Phiri S, Keiser O: Tracking of patients lost to follow-up and HIV transmission: mathematical modelling study based on two large ART programmes in Malawi. Journal of acquired immune deficiency syndromes (1999) 2014, 65(5):e179.
10. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, Montaner JS: Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002, 16(7):1051-1058.
11. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S, Jones JL: Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clinical Infectious Diseases 2000, 30(Supplement_1):S5-S14.
12. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS: Adherence to triple therapy and viral load response. JAIDS Journal of Acquired Immune Deficiency Syndromes 2000, 23(4):360-361.
13. Taiwo B: Understanding transmitted HIV resistance through the experience in the USA. International Journal of Infectious Diseases 2009, 13(5):552-559.
14. Teshale AB, Tsegaye AT, Wolde HF: Incidence and predictors of loss to follow up among adult HIV patients on antiretroviral therapy in University of Gondar Comprehensive Specialized Hospital: A competing risk regression modeling. PLoS One 2020, 15(1):e0227473.
15. Mekonnen N, Abdulkadir M, Shumetic E, Baraki AG, Yenit MK: Incidence and predictors of loss to follow-up among HIV infected adults after initiation of first line anti-retroviral therapy at University of Gondar comprehensive specialized Hospital Northwest Ethiopia, 2018: Retrospective follow up study. BMC Research Notes 2019, 12(1):1-7.
16. Mohammed A, Abdi S, Palani S, Joseph NM: Moderate incidence of lost follow-up and risk factors among adult HIV patients on second-line ART regimens in Amhara region hospitals, Ethiopia. Journal of Drug Delivery and Therapeutics 2019, 9(1-s):52-59.
17. Bikoro B, Olijira L, Gobena T, Erkalo D: Incidence and predictors of loss to follow-up among human immunodeficiency virus-infected adult patients on anti-retroviral therapy at Hadiya zone public hospitals, southern Ethiopia: a retrospective cohort study. Journal of Public Health 2020:1-12.
18. Berheto TM, Haile DB, Mohammed S: Predictors of loss to follow-up in patients living with HIV/AIDS after initiation of antiretroviral therapy. North American journal of medical sciences 2014, 6(9):453.
19. Kalinjuma AV, Glass TR, Weisser M, Myeya SJ, Kasuga B, Kisung’a Y, Sikalengo G, Katende A, Battegay M, Vanobberghen F: Prospective assessment of loss to follow-up: incidence and associated factors in a cohort of HIV-positive adults in rural Tanzania. Journal of the International AIDS Society 2020, 23(3):e25460.
20. Kiwanuka J, Mukulu Waila J, Muhindo Kahungu M, Kitonsa J, Kiwanuka N: Determinants of loss to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: A retrospect-
tive cohort study in Masaka, Uganda. *PLoS One* 2020, 15(4):e0217606.

21. Schepens T, Morreel S, Florence E, Koole O, Colebunders R: Incidence and risk factors associated with lost to follow-up in a Belgian cohort of HIV-infected patients treated with highly active antiretroviral therapy. *International journal of STD & AIDS* 2010, 21(11):765-769.

22. Alvarez-Uria G, Naik PK, Pakam R, Midde M: Factors associated with attrition, mortality, and loss to follow-up after antiretroviral therapy initiation: data from an HIV cohort study in India. *Global Health Action* 2013, 6(1):21682.

23. Li MS, Musonda P, Gartland M, Mulenga PL, Mwango A, Stringer JS, Chi BH: Predictors of patient attrition according to different definitions for loss to follow-up: a comparative analysis from Lusaka, Zambia. *Journal of acquired immune deficiency syndromes* (1999) 2013, 63(3):e116.

24. Ojwang’ V, Penner J, Blat C, Agot K, Bukusi E, Cohen C: Loss to follow-up among youth accessing outpatient HIV care and treatment services in Kisumu, Kenya. *AIDS Care* 2016, 28(4):500-507.

25. Assemie MA, Muchie KF, Ayele TA: Incidence and predictors of loss to follow up among HIV-infected adults at Pawi General Hospital, northwest Ethiopia: competing risk regression model. *BMC Research Notes* 2018, 11(1):287.

26. NORTH SHEWA ZONE. 2020. North Shewa Zone (Amhara) [Online]. Available: https://en.wikipedia.org/wiki/North Shewa Zone (Amhara) [Accessed 09/02/2020 2020].

27. Tadesse K, Fisila H: Predictors of loss to follow up of patients enrolled on antiretroviral therapy: a retrospective cohort study. *J. AIDS Clin Res* 2014, 5(393):2.

28. Yende-Zuma N, Naidoo K: The Effect of Timing of Initiation of Antiretroviral Therapy on Loss to Follow-up in HIV–Tuberculosis Coinfected Patients in South Africa: An Open-Label, Randomized, Controlled Trial. *AIDS Journal of Acquired Immune Deficiency Syndromes* 2016, 72(4):430-436.

29. Honge BL, Jespersen S, Nordentoft PB, Medina C, da Silva D, da Silva ZJ, Østergaard I, Laursen AL, Wejse C, group BHcs: Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. *BMJ Open* 2013, 3(10).

30. Eguzo K, Lawal A, Umezurike C, Eseigbe C: Predictors of Loss to Follow up Among HIV infected Patients in a Rural South Eastern Nigeria Hospital: A 5 year Retrospective Cohort Study. *Annals of Medical and Health Sciences Research* 2015, 5(6):373-378.

31. Tamara-Ramirez JR, Alvarez CA, Rodriguez J: Loss of follow-up and associated factors in patients enrolled in the HIV/AIDS program of the Hospital Universitario San Ignacio, Colombia, 2012-2013. *Bionmedica* 2016, 36(2):265-275.

32. Sciuf W, Ali W, Meresa B: Predictors of loss to follow up among adult clients attending antiretroviral treatment at Karamara general hospital, Jigjiga town, Eastern Ethiopia, 2015: a retrospective cohort study. *BMC Infections Diseases* 2018, 18(1):280.

33. Chi BH, Yiannoutsos CT, Westfall AO, Newman JE, Zhou J, Cesar C, Brinkhof MW, Mwango A, Balestre E, Carriquiry G: Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. *PLoS Med* 2011, 8(10):e1001111.

34. Chi BH, Cantrell RA, Mwango A, Westfall AO, Mutele W, Limbada M, Mulenga LB, Vermund SH, Stringer JS: An empirical approach to defining loss to follow-up among patients enrolled in antiretroviral treatment programs. *American journal of epidemiology* 2010, 171(8):924-931.

35. Birhanu MY, Leshargie CT, Abebe A, Wagnew F, Siferih M, Gebre T, Kibret GD: Incidence and predictors of loss to follow-up among HIV-positive adults in northwest Ethiopia: a retrospective cohort study. *Tropical Medicine and Health* 2020, 48(1):1-10.

36. Huang D, Zheng W, Yang J, Li Y, Hu A, Xu Z: Study on the prevalence of loss to follow-up and risk factors among human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) patients in Baoshan city, Yunnan province. Zhonghgu yu Fang yi xue za zhi [Chinese Journal of Preventive Medicine] 2014, 48(8):688-692.

37. Nicole L, Ly PS, Van Nguyen K, Merati TP, Pham TT, Lee MP, Choi JY, Ross J, Law MG, Ng OT: Loss to follow-up trends in HIV-positive patients receiving antiretroviral treatment in Asia from 2003 to 2013. *Journal of acquired immune deficiency syndromes* (1999) 2017, 74(5):555.

38. Fuente-Soro L, López-Varela E, Augusto O, Bernando EL, Sácoor C, Nhalolo A, Ruiz-Castillo P, Alfredo C, Karajeanes E, Vaz P: Loss to follow-up and opportunities for reengagement in HIV care in rural Mozambique: A prospective cohort study. *Medicine* 2020, 99(20):e20236.

39. World Health Organization: Global update on HIV
40. Wekesa P, McLigeyo A, Owuor K, Mwangi J, Nganga E, Masamaro K: Factors associated with 36-month loss to follow-up and mortality outcomes among HIV-infected adults on antiretroviral therapy in Central Kenya. *BMC Public Health* 2020, 20(1):1-11.

41. Langford SE, Ananworanich J, Cooper DA: Predictors of disease progression in HIV infection: a review. *AIDS Research and Therapy* 2007, 4(1):11.

42. Naidoo K, Yende-Zuma N, Augustine S: A retrospective cohort study of body mass index and survival in HIV infected patients with and without TB co-infection. *Infectious Diseases of Poverty* 2018, 7(1):35.

43. Martinez S, Campa A, Bussmann H, Moyo S, Makhema J, Huffman F, Williams O, Essex M, Marlink R, Baum M: Effect of BMI and fat mass on HIV disease progression in HIV-infected, antiretroviral treatment-naive adults in Botswana. *British Journal of Nutrition* 2016, 115(12):2114-2121.

44. Agolory SG, Auld AF, Odafe S, Shiraishi RW, Doku-Bo EK, Swaminathan M, Dalhatu I, Onotu D, Abiri O, Debem H: High rates of loss to follow-up during the first year of pre-antiretroviral therapy for HIV patients at sites providing pre-ART care in Nigeria, 2004–2012. *PLoS One* 2017, 12(9):e0183823.

45. Odafe S, Idoko O, Badru T, Aiyenigba B, Suzuki C, Khamofu H, Onyekwena O, Okechukwu E, Torpey K, Chabikuli ON: Patients’ demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals. *Journal of the International AIDS Society* 2012, 15(2):17424.

46. Megerso A, Garoma S, Tolosa Eticha TW, Daba S, Tarekegn M, Habtamu Z: Predictors of loss to follow-up in antiretroviral treatment for adult patients in the Oromia region, Ethiopia. *HIV/AIDS* (Auckland, NZ) 2016, 8:83.

47. Wilhelmson S, Reepalu A, Tolera Balcha T, Jarso G, Björkman P: Retention in care among HIV-positive patients initiating second-line antiretroviral therapy: a retrospective study from an Ethiopian public hospital clinic. *Global Health Action* 2016, 9(1):29943.

48. Arnesen R, Moll AP, Shenoi SV: Predictors of loss to follow-up among patients on ART at a rural hospital in KwaZulu-Natal, South Africa. *PLoS One* 2017, 12(5):e0177168.

49. Bucciardini R, Fragola V, Abegaz T, Lucattini S, Halifom A, Tadesse E, Berhe M, Pugliese K, Fuelli L, Di Gregorio M: Predictors of attrition from care at 2 years in a prospective cohort of HIV-infected adults in Tigray, Ethiopia. *BMJ global health* 2017, 2(3):e000325.

50. Lawn SD, Bekker L-G, Miller RF: Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. *The Lancet infectious diseases* 2005, 5(6):361-373.

51. Kitonsa J, Mayanja Y, Ailing E, Kiwanuka J, Namutundu J, Anywaine Z, Ggayi A-B, Kibengo F, Kiwanuka N, Kaleebu P: Factors affecting mortality among HIV positive patients two years after completing recommended therapy for Cryptococcal meningitis in Uganda. *PLoS One* 2019, 14(1):e0210287.

52. Goulet JL, Fultz SL, Rimland D, Butt A, Gibert C, Rodriguez-Barradas M, Bryant K, Justice AC: Do patterns of comorbidity vary by HIV status, age, and HIV severity? *Clinical Infectious Diseases* 2007, 45(12):1593-1601.

53. Lorenc A, Ananthavarathan P, Lorigan J, Banarsee R, Jowata M, Brook G: The prevalence of comorbidities among people living with HIV in Brent: a diverse London Borough. *London journal of primary care* 2014, 6(4):84-90.

54. Gonah L, Moodley I, Hlongwana K: Effects of HIV and non-communicable disease comorbidity on healthcare costs and health experiences in people living with HIV in Zimbabwe. *Southern African Journal of HIV Medicine* 2020, 21(1):1-8.